Introduction to the Burden of Recurrent Cystitis and Rationale for Prevention

Narrative Summary of Selected Presentations given at the OM Pharma/Vifor Pharma URO-VAXOM® Summit, held in Buenos Aires, Argentina, on 26th–27th April 2014

Enrique Patricio Ubertazzi,1 Björn Wullt,2 José Tirán-Saucedo3

1. Urogynaecology Section, Italian Hospital of Buenos Aires, Buenos Aires, Argentina
2. Section of MIG, Lund University, Lund, Sweden
3. Department of Obstetrics and Gynaecology, Christus Muguerza-Conchita Hospital; Mexican Institute of Infectious Diseases in Obstetrics and Gynaecology, Monterrey, Mexico

Disclosure: The authors are global consultants of OM/Vifor Pharma Company, Meyrin, Switzerland.
Acknowledgements: Assistance was provided by Ewen Legg, ApotheCom ScopeMedical.
Support: The publication of this article was funded by OM/Vifor Pharma. The views and opinions expressed are those of the authors and not necessarily those of OM/Vifor Pharma.
Citation: EMJ Urol. 2014;1(Suppl 2):14-21.

Summary

This educational summit, supported by an independent grant from OM/Vifor Pharma, brought together experts in the field of urology and gynaecology from Europe and Latin America to meet and discuss the cutting edge management of patients suffering from recurrent urinary tract infections (rUTIs). The meeting included plenary lectures as well as workshops and interactive sessions, allowing delegates and presenters to debate the most pressing international and local issues in the field.

50% of women experience at least one UTI in their lifetime; 25% and 44% of these patients will suffer recurrence of infection within 6 months and 1 year, respectively. It is estimated that rUTI affects up to 10% of otherwise healthy women.1 Data from epidemiologic studies suggest that each episode of acute cystitis in young women is associated with approximately 6.1 days of symptoms, 2.9 days of restricted activity, 1.2 days of inability to attend classes or work, and 0.4 days of bed rest. This may represent a burden for the patients. Furthermore, the management of each repeated infection leads to healthcare system expenditures. Given the level of prevalence and recurrence, assessment of the burden of UTI at both an individual and societal level and the identification of prophylactic measures to ameliorate this burden are essential for the effective management of rUTI.

Download (PDF, 115KB)

Comments are closed.